Camidanlumab

Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599) . Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1].

Product Specifications

CAS Number

[921618-45-3]

Product Name Alternative

HuMax-TAC

UNSPSC

12352203

Target

ADC Antibody; Interleukin Related; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/camidanlumab.html

Purity

99.23

Solubility

10 mM in DMSO

Smiles

[Camidanlumab]

Molecular Weight

(143.98 kDa)

References & Citations

[1]Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15 (11) :2709-2721.